Inhibitors of beta-amyloid aggregation: Still an issue of structure and function?

Drug Discovery Today: Therapeutic Strategies

Volumn 1, Issue 1, 2004, Pages 7-12

  Talaga, Patrice ^a  

^a UCB PHARMA   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

22 HYDROXYCHOLESTEROL; ALPHA SECRETASE; ALZHEIMER DISEASE VACCINE; AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; BETA SECRETASE INHIBITOR; CLIOQUINOL; CYCLODEXTRIN DERIVATIVE; ENZYME INHIBITOR; GINKGO BILOBA EXTRACT; HOMOTAURINE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY AMYLOID; PPI 1019; PROTEIN INHIBITOR; SP 233; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ARTICLE; CLINICAL TRIAL; CYTOSOL; DEMENTIA; DIZZINESS; DRUG DESIGN; DRUG PROTEIN BINDING; ENCEPHALITIS; GINKGO BILOBA; HUMAN; IMMUNIZATION; MENINGITIS; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; OLIGOMERIZATION; PATHOGENESIS; PROTEIN AGGREGATION; PROTEIN ASSEMBLY; PROTEIN BINDING; PROTEIN FUNCTION; PROTEIN STRUCTURE; TINNITUS;

EID: 13444266289     PISSN: 17406773     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ddstr.2004.05.002     Document Type: Review

References (45)

1. Nussbaum R.L. Ellis C.E. Alzheimer's disease and Parkinson's disease N. Engl. J. Med 348 2003 1356-1364
2. Hardy J. Selkoe D.J. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics Science 297 2002 353-356
3. Hardy J.A. Higgins G.A. Alzheimer's disease: The amyloid cascade hypothesis Science 256 1992 184-185
4. Lambert M.P. et al. Diffusible, non-fibrillar ligands derived from Aβ1-42 are potent central nervous system neurotoxins Proc. Natl. Acad. Sci. U.S.A 95 1998 6448-6453
5. Walsh D.M. et al. Amyloid beta-protein fibrillogenesis. Structure and biological activity of protofibrillar intermediates J. Biol. Chem 274 1999 25945-25952
6. Hoshi M. et al. Spherical aggregates of β-amyloid (amylospheroid) show high neurotoxicity and activate tau protein kinase I/glycogen synthase kinase-3β Proc. Natl. Acad. Sci. U.S.A 100 2003 6370-6375
7. Walsh D.M. et al. Naturally secreted oligomers of amyloid β protein potently inhibit hippocampal long-term potentiation in vivo Nature 416 2002 535-539
8. Walsh D.M. et al. Amyloid beta-protein fibrillogenesis. Detection of a protofibrillar intermediate J. Biol. Chem 272 1997 22364-22372
9. Harper J.D. et al. Observation of metastable Abeta amyloid protofibrils by atomic force microscopy Chem. Biol 4 1997 119-125
10. Caughey B. Lansbury P.T. Protofibrils, pores, fibrils and neurodegeneration: Separating responsible protein aggregates from the innocent bystanders Annu. Rev. Neurosci 26 2003 267-298
11. Lashuel H.A. et al. Neurodegenerative disease: Amyloid pores from pathogenic mutations Nature 418 2002 291
12. Gong Y. et al. Alzheimer's disease-affected brain: Presence of oligomeric Aβ ligands (ADDLs) suggests a molecular basis for reversible memory loss Proc. Natl. Acad. Sci. U.S.A 100 2003 10417-10422
13. Klein W.L. et al. Aβ toxicity in Alzheimer's disease: Globular oligomers (ADDLs) as new vaccine and drug targets Neurochem. Int 41 2002 345-352
14. Bitan G. et al. Amyloid β-protein (Aβ) assembly: Aβ40 and Aβ42 oligomerize through distinct pathways Proc. Nat. Acad. Sci. U.S.A 100 2003 330-335
15. Conde S. β-Amyloid peptide as a target for treatment of Alzheimer's disease Exp. Opin. Ther. Patents 12 2002 503-512
16. Talaga P. β-Amyloid aggregation inhibitors for the treatment of Alzheimer's disease: Dream or reality? Mini-Rev. Med. Chem 1 2001 175-186
17. Soto-Jara C. (2004) Beta sheet breaker peptide analogs that inhibit beta pleated sheet formation in amyloid beta-peptide. Patent application No: US6689753, Axonyx Inc
18. Permanne B. et al. Reduction of amyloid load and cerebral damage in a transgenic mouse model of Alzheimer's disease by treatment with a β-sheet breaker peptide FASEB J 16 2002 860-862
19. Findeis M.A. et al. Peptide inhibitors of beta amyloid aggregation Curr. Topic Med. Chem 2 2002 417-423
20. Arico-Muendel C.C. et al. (2004) Modulators of beta-amyloid peptide aggregation comprising D-aminoacids. Patent application No: US6689752, Praecis Pharmaceutical Inc
21. Geerts H. NC-531 neurochem Curr. Opin. Invest. Drugs 5 2004 95-100
22. Gerolymatos P.N. (1998) Use of the chelating agent clioquinol for the manufacture of a pharmaceutical composition for the treatment of Alzheimer's disease. Patent application No: WO98/06403, Gerolymatos PN SA
23. Ritchie C.W. et al. Metal-protein attenuation with iodochlorhydroxyquin (clioquinol) targeting Aβ amyloid deposition and toxicity in Alzheimer's disease Arch. Neurol 60 2003 1685-1691
24. Bush A.I. Metal complexing agents as therapies for Alzheimer's disease Neurobiol. Aging 23 2002 1031-1038
25. Morgan, T.E. and Kraft G.A. (2002) Emerging themes in Alzheimer's disease: Paradigm shift in drug discovery. Annu. Rep. Med. Chem. 37, 31-40
26. Bitan G. et al. Elucidation of primary structure elements controlling early amyloid β-protein oligomerization J. Biol. Chem 278 2003 34882-34889
27. Chang L. et al. Femtomole immunodetection of synthetic and endogenous amyloid-β oligomers and its application to Alzheimer's disease drug candidate screening J. Mol. Neurosci 20 2003 305-313
28. Chang L. et al. (2003). Composition useful for treating learning and/or memory disorders, degenerative diseases e.g. Alzheimer's disease, comprises antibodies that interact with soluble, non-fibrillar oligomeric assemblies of amyloid beta proteins. Patent application No. US2003068316, Northwestern University
29. Yao Z.X. et al. The Gingko biloba extract EGb 761 rescues the PC12 neuronal cells from β-amyloid-induced cell death by inhibiting the formation of β-amyloid-derived diffusible neurotoxic ligands Brain Res 889 2001 181-190
30. Chromy B.A. et al. Self-assembly of Aβ1-42 into globular neurotoxins Biochemistry 42 2003 12749-12760
31. Ono K. et al. Potent anti-amyloidogenic and fibril-destabilizing effects of polyphenols in vitro: Implications for the prevention and therapeutics of Alzheimer's disease J. Neurochem 87 2003 172-181
32. Greeson J. et al. (2003) Neuroprotective Spirostenol Pharmaceutical Compositions. Patent application No: WO03077869, Samaritan Pharmaceuticals Inc.
33. Golde T.E. Alzheimer disease therapy: Can the amyloid cascade be halted? J. Clin. Invest 111 2003 11-18
34. Konietzko H.C. et al. Antibodies against beta-amyloid slow cognitive decline in Alzheimer's disease Neuron 38 2003 517-518
35. Chain D.G. et al. [Mindset Biopharmaceuticals] (2003) Specific Antibodies to Amyloid beta Peptide, Pharmaceutical Compositions and Methods of Use Thereof. Patent application No: WO03074081
36. Wermuth C.G. Selective optimization of side activities: Another way for drug discovery J. Med. Chem 47 2004 1-12
37. Lashuel H.A. et al. New class of inhibitors of amyloid-β Fibril formation J. Biol. Chem 277 2002 42881-42890
38. Talaga P. Quéré L. The plasma membrane: A target and hurdle for the development of anti-Aβ drugs? Curr. Drug Targets - CNS & Neurol. Disorders 1 2002 565-572
39. Esteban J.A. Living with the enemy: A physiological role for the β-amyloid peptide Trends Neurosci 27 2004 1-3
40. Plant L.D. et al. The production of amyloid β peptide is a critical requirement for the viability of central neurons J. Neurosci 23 2003 5531-5535
41. Palmer A.M. Pharmacotherapy for Alzheimer's disease: Progress and prospects Trends Pharm. Sci 23 2002 426-433
42. Michaelis M.L. Drugs targeting Alzheimer's disease: Some things old and some things new J. Pharmacol. Exp. Ther 304 2003 897-904
43. Monsonego A. Weiner H.L. Immunotherapeutic approaches to Alzheimer's disease Science 302 2003 834-846
44. Dominguez D.I. De Strooper B. Novel therapeutic strategies provide the real test for the amyloid hypothesis of Alzheimer's disease Trends Pharm. Sci 23 2002 324-330
45. Barrow C.J. Advances in the development of Aβ-related therapeutic strategies for Alzheimer's disease Drugs News Perspect 15 2002 102-109